EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

Search

Sanofi SA

Fermé

SecteurSoins de santé

99.62 -0.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

99.51

Max

101.9

Chiffres clés

By Trading Economics

Revenu

-2.3B

499M

Ventes

-6.5B

7.6B

P/E

Moyenne du Secteur

23.216

63.778

BPA

1.31

Rendement du dividende

3.79

Marge bénéficiaire

6.539

Employés

82,878

EBITDA

-3.7B

563M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+15.12% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.79%

2.39%

Prochains Résultats

24 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-6B

125B

Ouverture précédente

100.18

Clôture précédente

99.62

Sentiment de l'Actualité

By Acuity

33%

67%

106 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Sanofi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mars 2025, 06:43 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5 févr. 2025, 13:41 UTC

Résultats

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5 févr. 2025, 07:10 UTC

Résultats

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5 févr. 2025, 06:39 UTC

Résultats

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

2 avr. 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mars 2025, 06:19 UTC

Market Talk
Résultats

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mars 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mars 2025, 09:00 UTC

Actualités

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mars 2025, 06:04 UTC

Acquisitions, Fusions, Rachats

Sanofi to Pay $600M Upfront

20 mars 2025, 06:02 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mars 2025, 06:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mars 2025, 09:33 UTC

Actions en Tendance

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mars 2025, 23:00 UTC

Actualités

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mars 2025, 09:50 UTC

Résultats

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mars 2025, 09:49 UTC

Résultats

Santander Increased 2024 Cash Payments by 19%

24 févr. 2025, 08:56 UTC

Market Talk
Résultats

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 févr. 2025, 08:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19 févr. 2025, 06:35 UTC

Acquisitions, Fusions, Rachats

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 févr. 2025, 06:34 UTC

Acquisitions, Fusions, Rachats

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 févr. 2025, 06:34 UTC

Acquisitions, Fusions, Rachats

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 févr. 2025, 06:32 UTC

Acquisitions, Fusions, Rachats

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 févr. 2025, 06:31 UTC

Acquisitions, Fusions, Rachats

Sanofi, CD&R Sign Opella Share Purchase Agreement

14 févr. 2025, 10:55 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5 févr. 2025, 07:48 UTC

Market Talk
Résultats

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

Comparaison

Variation de prix

Sanofi SA prévision

Objectif de Prix

By TipRanks

15.12% hausse

Prévisions sur 12 Mois

Moyen 115.584 EUR  15.12%

Haut 125 EUR

Bas 92 EUR

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

9

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

100.38 / 101.44Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

106 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.